Medincell SA (MEB.BE)
| Previous close | 15.40 |
| Open | 15.42 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 14.84 - 15.42 |
| 52-week range | 5.42 - 16.78 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV & PARIS, May 08, 2024--ACCESS HERE THE COMPLETE PRESS RELEASE
- Business Wire
Medincell announces the suspension of listing of its shares on Euronext Paris
MONTPELLIER, France, May 08, 2024--Regulatory News: The listing of the Medincell (Paris:MEDCL) shares on Euronext Paris has been suspended at the request of the Company, pending the publication of a press release. Trading on Euronext Paris will resume tomorrow at the opening of markets.
Business WireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France, April 16, 2024--Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. AbbVie will financ
